<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04156685</url>
  </required_header>
  <id_info>
    <org_study_id>A84_07BE1908</org_study_id>
    <nct_id>NCT04156685</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics, Safety and Tolerability of CKD-387 10/500mg BE Phase1</brief_title>
  <official_title>An Open-label, Rendomized, Single-dose Crossover Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-387 in Healthy Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the pharmacokinetics, safety and tolerability of
      CKD-387
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open-label, randomized, single-dose crossover study to evaluate the pharmacokinetics,
      safety and tolerability of CKD-387 in helalthy subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 6, 2019</start_date>
  <completion_date type="Actual">October 2, 2019</completion_date>
  <primary_completion_date type="Actual">August 30, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>2 part, 2x2 crossover study</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A : Cmax under fasting condition</measure>
    <time_frame>0(predose)~48 hours</time_frame>
    <description>Maximum concentration of the dapagliflozin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A : Cmax under fasting condition</measure>
    <time_frame>0(predose)~48 hours</time_frame>
    <description>Maximum concentration of the metformin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A : AUClast under fasting condition</measure>
    <time_frame>0(predose)~48 hours</time_frame>
    <description>Area Under Curve(last) of the dapagliflozin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A : AUClast under fasting condition</measure>
    <time_frame>0(predose)~48 hours</time_frame>
    <description>Area Under Curve(last) of the metformin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B : Cmax under fed condition</measure>
    <time_frame>0(predose)~48 hours</time_frame>
    <description>Maximum concentration of the metformin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B : AUClast under fed condition</measure>
    <time_frame>0(predose)~48 hours</time_frame>
    <description>Area Under Curve(last) of the metformin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part A : AUCinf under fasting condition</measure>
    <time_frame>0(predose)~48 hours</time_frame>
    <description>Area Under Curve(infinit) of the dapagliflozin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A : AUCinf under fasting condition</measure>
    <time_frame>0(predose)~48 hours</time_frame>
    <description>Area Under Curve(infinit) of the metformin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A : Tmax under fasting condition</measure>
    <time_frame>0(predose)~48 hours</time_frame>
    <description>Time of maximum concentration of the dapagliflozin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A : Tmax under fasting condition</measure>
    <time_frame>0(predose)~48 hours</time_frame>
    <description>Time of maximum concentration of the metformin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A : t1/2 under fasting condition</measure>
    <time_frame>0(predose)~48 hours</time_frame>
    <description>Half life of the dapagliflozin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A : t1/2 under fasting condition</measure>
    <time_frame>0(predose)~48 hours</time_frame>
    <description>Half life of the metformin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B : AUCinf under fed condition</measure>
    <time_frame>0(predose)~48 hours</time_frame>
    <description>Area Under Curve(infinit) of the metformin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B : Tmax under fed condition</measure>
    <time_frame>0(predose)~48 hours</time_frame>
    <description>Time of Maximum concentration of the metformin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B : t1/2 under fed condition</measure>
    <time_frame>0(predose)~48 hours</time_frame>
    <description>Half life of the metformin</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Type2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>PartA, Treatment-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1 : Reference drug Period 2 : Test drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PartA, Treatment-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1 : Test drug Period 2 : Reference drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PartB, Treatment-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1 : Reference drug Period 2 : Test drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PartB, Treatment-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1 : Test drug Period 2 : Reference drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part A, Reference (D635 10/500mg, Astrazeneca)</intervention_name>
    <description>Once a day. Under fasting condition</description>
    <arm_group_label>PartA, Treatment-1</arm_group_label>
    <other_name>PartA, Test(CKD-387 10/500mg)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part A, Reference (D635 10/500mg, Astrazeneca)</intervention_name>
    <description>Once a day. Under fasting condition</description>
    <arm_group_label>PartA, Treatment-2</arm_group_label>
    <other_name>PartA, Test(CKD-387 10/500mg)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part B, Reference (D635 10/500mg, Astrazeneca)</intervention_name>
    <description>Once a day. Under fed condition</description>
    <arm_group_label>PartB, Treatment-1</arm_group_label>
    <other_name>PartB, Test(CKD-387 10/500mg)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part B, Reference (D635 10/500mg, Astrazeneca)</intervention_name>
    <description>Once a day. Under fed condition</description>
    <arm_group_label>PartB, Treatment-2</arm_group_label>
    <other_name>PartB, Test(CKD-387 10/500mg)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy adult older than 19 years and less than 45 years at the time of screening.

          2. BMI 18.5~29.9 kg/m2 and body weight more than 50kg.

          3. Subjects who have consented to the use of appropriate double- pregnancy contraceptive
             methods up to one months after the last investigational product and not to provide
             sperm for men.

          4. Subjects who sign on an informed consent form willingly.

        Exclusion Criteria:

          1. Subjects who have a clinically significant disease or medical history such as
             respiratory, hepatic, kidneys, blood, gastrointestinal, endocrine, immune system,
             skin, nervous and mental disease.

          2. Subjects who have acute disease within 28 days prior to the first administration.

          3. Subjects who have history that may affect the ADME.

          4. Subjects who have medical history or medical abuse history of hypersensitivity from
             SGLT inhibitors or Biguanides including Metformin or other medications(Aspirin,
             Antibiotics etc.).

          5. Subjects who have clinically significant chronic disease.

          6. Subjects with genetic problems such as galactose intolerance, Lapp lactase deficiency
             or glucose-galactose mal-absorption.

          7. Subjects whose laboratory test result are same as below;

               -  AST,ALT &gt; UNL(Upper Normal Limit)x3

               -  Fasting glucose level out of 70-125mg/dl

               -  Creatinine clearance is lower than 80mL/min which is calcuated by Cockcroft-Gault
                  formulation.

               -  QT&gt;450msec

               -  Positive urine hCG(female).

          8. Subjects whoes blood pressure exceeds out of normal range as below at screening.

               -  SBP : over 100mmHg, under 160mmHg

               -  DBP : over 60mmHg, under 100mmHg

          9. Subjects who have been found to be positive in serological tests(HBs antigen, HCV
             antibody and HIV antibody).

         10. Subjects who took ETC(Ethical Drug), oriental medicine within 2 weeks prior to the
             first administration of investigational products.

         11. Subjects who took OTC(Over-the-counter Drug, including korean galenical drug) within
             10 days prior to the first administration of investigational products.

         12. Subjects who have allergic disease which has clinical significance(But, light allergic
             rhinitis and ligth allergic dermatitis which do not need medication is exceptional).

         13. Subjects who can not eat standard meals provided by the institution.

         14. Subjects who donated whole blood within 60 days, donated the blood components within
             20 days prior to the first administration of investigational products.

         15. Subjects who received blood transfusion within 30 days prior to the first
             administration of investigational products.

         16. Subjects who were participated in the other clinical trial within 90 days prior to the
             first administration of investigational products.

         17. Subjects who took medication for the induction and inhibition of metabolizing enzymes
             such as barbiturate drugs within 6months prior to the first administration of
             investigational products.

         18. Subjects who have had abnormal diets that can affect the ADME of the drug within 30
             days prior to the first administration of investigational products. (Ingestion of
             grapefruit juice&gt;1L/day or Caffein&gt;5Cups/day).

         19. Subjects who have took regular alcohol(alcohol&gt;30g/day) prior to the first
             administration of investigational products.

         20. Subjects who smoked more than 10 cigarettes per day prior 3months to the first
             administration of investigational products or cannot discontinue smoking during the
             clinical trial.

         21. Subjects who is determined unsuitable to participate in this clinical trial by the
             investigator.

         22. Lactating Women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ji-Young Park, M.D, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University Anam Hospital / Seoul, Seongbuk-Gu, South Korea</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Seongbuk-Gu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 6, 2019</study_first_submitted>
  <study_first_submitted_qc>November 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2019</study_first_posted>
  <last_update_submitted>November 6, 2019</last_update_submitted>
  <last_update_submitted_qc>November 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type2 Diabetes Mellitus</keyword>
  <keyword>CKD-387</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

